215298-74-1

Basic information

• Product Name: 1H-Pyrazole-3-carboxamide,4-amino-5-ethyl-(9CI)
• Synonyms: 1H-Pyrazole-3-carboxamide,4-amino-5-ethyl-(9CI);1H-Pyrazole-3-carboxamide,4-amino-5-ethyl-
• CAS NO: 215298-74-1
• Molecular Formula: C₆H₁₀N₄O
• Molecular Weight: 154.1698
• Product Categories: AMIDE
• Mol File: 215298-74-1.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1H-Pyrazole-3-carboxamide,4-amino-5-ethyl-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Pyrazole-3-carboxamide,4-amino-5-ethyl-(9CI)(215298-74-1)
• EPA Substance Registry System: 1H-Pyrazole-3-carboxamide,4-amino-5-ethyl-(9CI)(215298-74-1)

Safety Data

• Hazardous Substances Data: 215298-74-1(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
1H-Pyrazole-3-carboxamide,4-amino-5-ethyl-(9CI) is used as a building block in organic synthesis for the production of various pharmaceuticals and agrochemicals. Its unique structure allows for the creation of a wide range of compounds with potential applications in different industries.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 1H-Pyrazole-3-carboxamide,4-amino-5-ethyl-(9CI) serves as a key intermediate for the development of new drugs. Its presence in the synthesis process contributes to the creation of bioactive compounds with potential therapeutic effects.
Used in Pharmaceutical Industry:
1H-Pyrazole-3-carboxamide,4-amino-5-ethyl-(9CI) is used as a precursor in the pharmaceutical industry for the production of various medications. Its versatility in synthesis allows for the development of drugs with different mechanisms of action and therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical industry, 1H-Pyrazole-3-carboxamide,4-amino-5-ethyl-(9CI) is utilized as a starting material for the synthesis of agrochemicals, such as pesticides and herbicides. Its ability to form diverse compounds makes it a valuable asset in the development of effective and targeted agricultural products.

Upstream product

• 335078-01-8 2-propoxy-5-iodonicotinic acid 

Relevant articles and documents

Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterase (cGMP PDE5) for the treatment of sexual dysfunction

Compounds of formulae (IA) and (IB) or pharmaceutically or veterinarily acceptable salts thereof, or pharmaceutically or veterinarily acceptable solvates of either entity, wherein R1 is C1 to C3 alkyl substituted with C3 to C6 cycloalkyl, CONR5R6 or a N-linked heterocyclic group; (CH2)nHet or (CH2)nAr; R2 is C1 to C6 alkyl; R3 is C1 to C6 alkyl optionally substituted with C1 to C4 alkoxy; R4 is SO2NR7R8; R5 and R6 are each independently selected from H and C1 to C4 alkyl optionally substituted with C1 to C4 alkoxy, or, together with the nitrogen atom to which they are attached, form a 5- or 6-membered heterocyclic group; R7 and R8, together with the nitrogen atom to which they are attached, form a 4-R10-piperazinyl group; R10 is H or C1 to C4 alkyl optionally substituted with OH, C1 to C4 alkoxy or CONH2; H is an optionally substituted C-linked 5- or 6-membered heterocyclic group; Ar is optionally substituted phenyl; and n is 0 or 1; are potent and selective cGMP PDE5 inhibitors useful in the treatment of, inter alia, male erectile dysfunction and female sexual dysfunction.

Pharmaceutically active compounds

There is provided a general formula I: or a pharmaceutically or veterinarily acceptable salt or polymorph and/or solvate thereof, wherein R1 represents H; C(O)C1-C4 alkyl; C(O)aryl; C(O)heteroaryl. and which is useful in the curative and prophylactic treatment of a medical condition for which inhibition of a cyclic guanosine 3′,5′-monophosphate phosphodiesterase (and in particular cGMP PDE5) is desired.

Novel process for the preparation of pyrazoles

A “one-pot” process is described herein for the production of pyrazole compounds of general formula (II) comprising the steps of reacting a compound of general formula (III) with an acylating agent in the presence of a base and an optional activating agent followed by the addition of a hydrazine compound in situ.